Branded Generics Market Outlook (2023 to 2033)

In 2023, the branded generics market is estimated to be worth US$ 327.8 million. The branded generics business is expected to reach US$ 747.2 million by 2033, capturing a CAGR of 8.6% during the forecast period.

Branded generics are the most recent versions of off-patent pharmaceuticals supplied by patented drug makers or generic drug businesses with strong brand awareness for their generic drug equivalents. Several internal and external licensing, production, and marketing characteristics characterize the pharmaceutical industry. The concept of patenting is vital to the pharmaceutical industry.

Some principal growth drivers are the rising frequency of chronic diseases, increased penetration of branded generic pharmaceuticals, increased government activities to promote generic products, and the expiration of significant drug patents.

The expiration of innovator medicine patent exclusivity creates chances for generic manufacturers to introduce goods at a lower cost. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending.

  • As Bristol-Myers Squibb Company's proprietary Sprycel (Dasatinib) patent exclusivity period expired in 2020, generic businesses such as Apotex and Dr. Reddy's Laboratories have filed ANDA to launch generic versions of the medicine.
Attributes Details
Branded Generics Market CAGR (2023 to 2033) 8.6%
Branded Generics Market Size - 2023 US$ 327.8 million
Branded Generics Market Size - 2033 US$ 747.2 million

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Historical Comparison for Branded Generics Industry between 2018 to 2022 and 2023 to 2033

The branded generics market is expected to record an 8.6% CAGR between 2023 and 2033, compared to a 6.9% CAGR from 2018 to 2022.

Global interest in branded generics has grown with rising healthcare expenses and a growing need for high-quality generic pharmaceuticals. The branded generics industry is primarily driven by drug patent expiration.

Consumer preference is critical to accelerating the expansion of the branded generic business. People prefer the greatest items they can afford. Brands command a high level of confidence, constant quality, and the fulfillment of a promise.

A branded generic is a generic medication through the Abbreviated New Drug Application (ANDA) process. The rising frequency of chronic diseases may boost demand for branded generics.

The changing lifestyle has increased the prevalence of cardiovascular diseases and other conditions such as diabetes and hypertension. As a result, sales of anti-hypersensitive branded generics have gradually increased.

  • According to the World Health Organisation (WHO), around 17.9 million people worldwide die each year as a result of cardiovascular illnesses (CVDs). Patients are migrating to branded generics to combat these diseases and reduce treatment costs.
Attributes Details
Market HCAGR (2018 to 2022) 6.9%
Market Size - 2017 US$ 217.6 billion
Market Size - 2022 US$ 304.2 billion

Generics on the Rise: Unveiling the Forces Escalating Branded Generics Market Growth

Rising demand for low-cost healthcare solutions in established and emerging economies accelerates market expansion. These drugs provide a good combination of cost-effectiveness and quality, making them appealing to patients and healthcare professionals.

The expiration of several blockbuster medicine patents has opened the door for generic producers to enter the market with their own branded copies. As a result, there is more competition and a more incredible selection of patient options.

The rising prevalence of chronic diseases and the requirement for long-term prescription use have aided in the growth of the branded generics industry. To address these therapeutic areas, pharmaceutical companies are working on producing branded generic medications.

A combination of affordability, patent expiration, and disease prevalence spurs market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Navigating the Branded Generics Maze: Regulatory, Competitive, and Counterfeit Challenges

Despite its potential for expansion, the branded generics market is constrained by several factors. The stringent regulatory standards set by various health authorities, which might create hurdles to entry for new businesses, are one fundamental cause. Meeting these requirements can be time-consuming and expensive, stifling market growth.

Another impediment is the presence of well-known brand-name pharmaceutical firms. These corporations frequently have significant brand loyalty and marketing resources, so generic manufacturers need help competing for market share and brand recognition.

The possibility of counterfeit and substandard products is a severe market challenge. The lack of effective quality control methods and the availability of low-cost alternatives might damage patient and healthcare professional trust, limiting the market's growth potential.

The key restraints for the branded generics industry include the following:

  • Regulatory barriers.
  • Competition from brand-name drugs.
  • The possibility of counterfeit products.

The Rise of Branded Generics: Unlocking Opportunities in Healthcare Cost Containment, Emerging Markets, Technology, and Partnerships

With the increased emphasis on healthcare cost containment, branded generics have an opportunity to play a substantial role. These prescriptions are less expensive than brand-name drugs, making them appealing to healthcare systems, insurers, and consumers.

The development of healthcare infrastructure and the rise in healthcare expenditure in emerging economies create new markets for branded generics. As these countries work to enhance access to cheap drugs, branded generics can help fulfill demand while delivering superior treatment options.

Technological and manufacturing process developments provide chances for generic producers to improve their production capacity, improve product quality, and provide novel dosage forms or delivery systems.

Collaborations and collaborations between generic producers and healthcare providers can generate synergies and assist branded generics in building a strong market presence, thereby boosting their reach and market share.

The potential for branded generics is in cost containment, emerging markets, technical developments, and collaborations with healthcare providers.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

2023 value share in Global Market:

Countries Value
North America 19.0%
Europe 25.0%

How Does China Plan To Sustain Its Market Dominance In Leading Branded Generics?

The low price and strong popularity of branded generic pharmaceuticals drive the Chinese pharmaceutical sector. China's drug evaluation and approval system has been streamlined, allowing more new local, innovative, and foreign drugs to enter the market.

The China market is very competitive, with the government overseeing medicine approval and development. Due to their cost-effective qualities, generic and branded generics are surging the industry in the country.

According to a work plan announced jointly by 12 government departments, including the National Health Commission, China may publish and update the list of generic pharmaceuticals at the end of each year.

2023 Value Share in Global Market:

Countries Value
United States 16.8%
Germany 2.9%
Japan 4.4%

What is the Current State of Demand for Branded Generics in India?

India is a leading exporter of generic medications to countries such as the United States, Europe, and Africa. Brand generic medicine manufacturers can develop and market generic pharmaceuticals at a considerably lower cost without sacrificing product quality.

  • According to the India Brand Equity Foundation, India's pharmaceutical business supplies more than half of the global demand for various vaccines, 40% of the generic demand in the United States, and 25% of all pharmaceuticals in the United Kingdom.

The pharmaceutical market in India is dominated by branded generics, resulting in generic-induced price competition. The rapid expansion of the market in India can also be ascribed to rising disposable income, increased demand for branded generics at affordable rates, and an increase in the prevalence of chronic diseases.

2023 Value CAGR in Global Market:

Countries Value
Australia 7.5%
China 10.4%
India 11.9%
United Kingdom 9.5%

Navigating Success: Why the United States is Poised for Credible Growth Opportunities?

The production of branded generics has expanded significantly in the United States since they are less expensive than branded pharmaceuticals and do not necessitate intensive research and testing. The rising prevalence of chronic conditions such as cardiovascular disease, diabetes, Alzheimer's disease, and Parkinson's disease in the country has provided the needed impetus to the branded generics business.

Category-wise Insights

Category Distribution Channel
Leading Segment Retail Pharmacies
Market Share 43.7%
Category Formulation Type
Leading Segment Oral
Market Share 54.0%
Category Therapy Area
Leading Segment Cardiovascular Diseases
Market Share 17.95%
Category Drug Class
Leading Segment Anti-Hypertensive
Market Share 27.53%

Branded Generics Market Responds to the Escalating Prevalence of Cardiovascular Diseases

Cardiovascular diseases (CVDs) and diabetes continue to be the most important therapeutic application areas, accounting for more than half of all branded generic sales in the global market.

  • According to the World Health Organisation (WHO), around 17.9 million people worldwide die each year as a result of cardiovascular illnesses (CVDs). Similarly, hypertension affects 1.13 billion people worldwide.

This leads to the adoption of branded generics, such as anti-hypertensive medicines, and the branded generics market.

Analyzing the Dominant Formulation Type in the Branded Generics Market

With a market share of 54%, the oral formulation sector dominates the branded generics industry. The convenience element connected with oral administration can be linked to the segment's rise.

Oral drugs are simple to deliver, and patient compliance is higher than other administration methods. Furthermore, sweeteners and colored coatings make tablets and capsules more appetizing.

FMI believes that the parental formulation may take center stage during the prediction period. By 2033, the parental category is predicted to lead the branded generics business.

Harnessing the Power of Online Pharmacies: Boosting Branded Generics Sales in the Digital Era

Future Market Insights has classified the demand for branded generics by distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

Manufacturers are forming relationships with online and retail pharmacies in response to the rise of e-commerce. An enormous COVID-19 epidemic normalized the purchase of branded generics from online pharmacies.

Patients find obtaining their medication directly from Internet pharmacies convenient and time-saving. As a result, online pharmacies are expected to grow in popularity through 2023 and beyond.

How can Manufacturers Scale their Businesses in the Branded Generics Market?

  • Increase Distribution Networks Manufacturers should form agreements with wholesalers, distributors, and pharmacies to ensure that their branded generics reach a wider market.
  • Marketing and Branding Effective marketing efforts can raise brand awareness and help products stand out. Building a strong brand image can lead to improved consumer trust and preference.
  • Strive for Strategic Alliances Collaboration with healthcare providers, insurance firms, and government organizations can result in greater market access and sales.
  • Concentrate on Regulatory Compliance Maintaining high-quality standards and ensuring compliance with relevant regulations can help to create trust with consumers and regulatory bodies.
  • Extensive Research and Development Creating new formulations, refining old products, and investing in innovation can provide you with a competitive advantage and help you attract more customers.
  • Enhance the Uniformity and Excellence of Products Delivering high-quality items consistently helps to establish client loyalty and strong word-of-mouth recommendations.
  • Carry out Market Research Understanding market trends, consumer preferences, and competition strategies can assist in informing product creation and aid in the targeting of certain customer categories.

Competitive Landscape

The absence of patent restrictions allows pharmaceutical companies to freely sell branded generics, leading to a significant influx of vendors in the global market. The competition within the branded generics business has remained predominantly positive, fostering growth and promoting collaboration among various pharmaceutical manufacturers. The leading branded generics manufacturers are expected to focus on expanding their product offerings by making substantial investments.

Key Branded Generics Manufacturers

  • Teva Pharmaceuticals Industries Ltd.
  • Abbott Laboratories
  • Novartis
  • Mylan
  • Pfizer

Recent Innovations and Developments

Company Dr. Reddy's Laboratories Ltd.
Strategy Product Launch
Details Dr. Reddy's Laboratories Ltd. may introduce Invista in India in April 2020. This is the branded generic equivalent of Sprycel (dasatinib), used to treat adult CML patients.
Company Teva Pharmaceuticals Industries Ltd.
Strategy Product Launch
Details Teva Pharmaceuticals Industries Ltd. and Hikma Pharmaceuticals PLC launched Tracleer generic in the United States in June 2019.
Company Teva Pharmaceutical Industries Ltd.
Strategy Product Launch
Details Teva Pharmaceutical Industries Ltd. announced the launching of the first generic version of THIOLA (tiopronin) tablets in the United States in May 2021. These tablets are intended to be used in conjunction with high fluid intake, alkali, and diet modification to prevent the formation of cystine (kidney) stones in adults and pediatric patients with severe homozygous cystinuria who are older than nine years old and are not responsive to these treatments alone.
Company Lupin
Strategy Acquisition
Details Lupin, a significant global pharmaceutical firm with a wholly-owned subsidiary in Australia, said in July 2021 that it had signed a legally binding agreement to acquire all of the outstanding shares of Southern Cross Pharma Pty Ltd (SCP) from SCP.

Key Segments

By Therapeutic Application:

  • Oncology
  • Cardiovascular Diseases
  • Diabetes
  • Neurology
  • Gastrointestinal Diseases
  • Dermatology Diseases
  • Analgesics and Anti-inflammatory
  • Others

By Drug Class:

  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others

By Formulation Type:

  • Oral
  • Parenteral
  • Topical
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • Asia Pacific Excluding Japan
  • The Middle East and Africa
  • Japan

Frequently Asked Questions

Which Region is likely to Lead the Branded Generics Market?

North America is likely to lead the branded generics industry.

By 2033, how much can the Branded Generics Industry Grow?

The branded generics market is estimated to surpass US$ 747.2 million by 2033.

What is the Current Valuation of the Branded Generics Market?

The branded generics industry is likely to record a value of US$ 327.8 million in 2023.

What is the Growth Outlook for Branded Generics Market?

The branded generics industry is likely to secure a CAGR of 8.6% through 2033.

Which industry is the key consumer of the branded generics market?

The pharmaceutical industry is the key consumer of the branded generics market.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Product Life Cycle Analysis

    3.5. Supply Chain Analysis

        3.5.1. Supply Side Participants and their Roles

            3.5.1.1. Producers

            3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)

            3.5.1.3. Wholesalers and Distributors

        3.5.2. Value Added and Value Created at Node in the Supply Chain

        3.5.3. List of Raw Material Suppliers

        3.5.4. List of Existing and Potential Buyer’s

    3.6. Investment Feasibility Matrix

    3.7. Value Chain Analysis

        3.7.1. Profit Margin Analysis

        3.7.2. Wholesalers and Distributors

        3.7.3. Retailers

    3.8. PESTLE and Porter’s Analysis

    3.9. Regulatory Landscape

        3.9.1. By Key Regions

        3.9.2. By Key Countries

    3.10. Regional Parent Market Outlook

    3.11. Production and Consumption Statistics

    3.12. Import and Export Statistics

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) & Volume ( Thousand Units) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic Application

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis By Therapeutic Application, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis and Forecast By Therapeutic Application, 2023 to 2033

        5.3.1. Oncology

        5.3.2. Cardiovascular Diseases

        5.3.3. Diabetes

        5.3.4. Neurology

        5.3.5. Gastrointestinal Diseases

        5.3.6. Dermatology Diseases

        5.3.7. Analgesics and Anti-inflammatory

        5.3.8. Others

    5.4. Y-o-Y Growth Trend Analysis By Therapeutic Application, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapeutic Application, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis By Drug Class, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis and Forecast By Drug Class, 2023 to 2033

        6.3.1. Alkylating Agents

        6.3.2. Antimetabolites

        6.3.3. Hormones

        6.3.4. Anti-Hypertensive

        6.3.5. Lipid Lowering Drugs

        6.3.6. Anti-Depressants

        6.3.7. Anti-Psychotics

        6.3.8. Anti-Epileptics

        6.3.9. Others

    6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Formulation Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis By Formulation Type, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis and Forecast By Formulation Type, 2023 to 2033

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Topical

        7.3.4. Others

    7.4. Y-o-Y Growth Trend Analysis By Formulation Type, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Formulation Type, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis By Distribution Channel, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis and Forecast By Distribution Channel, 2023 to 2033

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

        8.3.4. Drug Stores

    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    9.1. Introduction

    9.2. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis By Region, 2018 to 2022

    9.3. Current Market Size Value (US$ Million) & Volume ( Thousand Units) Analysis and Forecast By Region, 2023 to 2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Western Europe

        9.3.4. Eastern Europe

        9.3.5. South Asia and Pacific

        9.3.6. East Asia

        9.3.7. Middle East and Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. USA

            10.2.1.2. Canada

        10.2.2. By Therapeutic Application

        10.2.3. By Drug Class

        10.2.4. By Formulation Type

        10.2.5. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapeutic Application

        10.3.3. By Drug Class

        10.3.4. By Formulation Type

        10.3.5. By Distribution Channel

    10.4. Key Takeaways

11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Brazil

            11.2.1.2. Mexico

            11.2.1.3. Rest of Latin America

        11.2.2. By Therapeutic Application

        11.2.3. By Drug Class

        11.2.4. By Formulation Type

        11.2.5. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapeutic Application

        11.3.3. By Drug Class

        11.3.4. By Formulation Type

        11.3.5. By Distribution Channel

    11.4. Key Takeaways

12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Germany

            12.2.1.2. UK

            12.2.1.3. France

            12.2.1.4. Spain

            12.2.1.5. Italy

            12.2.1.6. Rest of Western Europe

        12.2.2. By Therapeutic Application

        12.2.3. By Drug Class

        12.2.4. By Formulation Type

        12.2.5. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapeutic Application

        12.3.3. By Drug Class

        12.3.4. By Formulation Type

        12.3.5. By Distribution Channel

    12.4. Key Takeaways

13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Poland

            13.2.1.2. Russia

            13.2.1.3. Czech Republic

            13.2.1.4. Romania

            13.2.1.5. Rest of Eastern Europe

        13.2.2. By Therapeutic Application

        13.2.3. By Drug Class

        13.2.4. By Formulation Type

        13.2.5. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Therapeutic Application

        13.3.3. By Drug Class

        13.3.4. By Formulation Type

        13.3.5. By Distribution Channel

    13.4. Key Takeaways

14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. India

            14.2.1.2. Bangladesh

            14.2.1.3. Australia

            14.2.1.4. New Zealand

            14.2.1.5. Rest of South Asia and Pacific

        14.2.2. By Therapeutic Application

        14.2.3. By Drug Class

        14.2.4. By Formulation Type

        14.2.5. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Therapeutic Application

        14.3.3. By Drug Class

        14.3.4. By Formulation Type

        14.3.5. By Distribution Channel

    14.4. Key Takeaways

15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. China

            15.2.1.2. Japan

            15.2.1.3. South Korea

        15.2.2. By Therapeutic Application

        15.2.3. By Drug Class

        15.2.4. By Formulation Type

        15.2.5. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Therapeutic Application

        15.3.3. By Drug Class

        15.3.4. By Formulation Type

        15.3.5. By Distribution Channel

    15.4. Key Takeaways

16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) & Volume ( Thousand Units) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) & Volume ( Thousand Units) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. GCC Countries

            16.2.1.2. South Africa

            16.2.1.3. Israel

            16.2.1.4. Rest of MEA

        16.2.2. By Therapeutic Application

        16.2.3. By Drug Class

        16.2.4. By Formulation Type

        16.2.5. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Therapeutic Application

        16.3.3. By Drug Class

        16.3.4. By Formulation Type

        16.3.5. By Distribution Channel

    16.4. Key Takeaways

17. Key Countries Market Analysis

    17.1. USA

        17.1.1. Pricing Analysis

        17.1.2. Market Share Analysis, 2022

            17.1.2.1. By Therapeutic Application

            17.1.2.2. By Drug Class

            17.1.2.3. By Formulation Type

            17.1.2.4. By Distribution Channel

    17.2. Canada

        17.2.1. Pricing Analysis

        17.2.2. Market Share Analysis, 2022

            17.2.2.1. By Therapeutic Application

            17.2.2.2. By Drug Class

            17.2.2.3. By Formulation Type

            17.2.2.4. By Distribution Channel

    17.3. Brazil

        17.3.1. Pricing Analysis

        17.3.2. Market Share Analysis, 2022

            17.3.2.1. By Therapeutic Application

            17.3.2.2. By Drug Class

            17.3.2.3. By Formulation Type

            17.3.2.4. By Distribution Channel

    17.4. Mexico

        17.4.1. Pricing Analysis

        17.4.2. Market Share Analysis, 2022

            17.4.2.1. By Therapeutic Application

            17.4.2.2. By Drug Class

            17.4.2.3. By Formulation Type

            17.4.2.4. By Distribution Channel

    17.5. Germany

        17.5.1. Pricing Analysis

        17.5.2. Market Share Analysis, 2022

            17.5.2.1. By Therapeutic Application

            17.5.2.2. By Drug Class

            17.5.2.3. By Formulation Type

            17.5.2.4. By Distribution Channel

    17.6. UK

        17.6.1. Pricing Analysis

        17.6.2. Market Share Analysis, 2022

            17.6.2.1. By Therapeutic Application

            17.6.2.2. By Drug Class

            17.6.2.3. By Formulation Type

            17.6.2.4. By Distribution Channel

    17.7. France

        17.7.1. Pricing Analysis

        17.7.2. Market Share Analysis, 2022

            17.7.2.1. By Therapeutic Application

            17.7.2.2. By Drug Class

            17.7.2.3. By Formulation Type

            17.7.2.4. By Distribution Channel

    17.8. Spain

        17.8.1. Pricing Analysis

        17.8.2. Market Share Analysis, 2022

            17.8.2.1. By Therapeutic Application

            17.8.2.2. By Drug Class

            17.8.2.3. By Formulation Type

            17.8.2.4. By Distribution Channel

    17.9. Italy

        17.9.1. Pricing Analysis

        17.9.2. Market Share Analysis, 2022

            17.9.2.1. By Therapeutic Application

            17.9.2.2. By Drug Class

            17.9.2.3. By Formulation Type

            17.9.2.4. By Distribution Channel

    17.10. Poland

        17.10.1. Pricing Analysis

        17.10.2. Market Share Analysis, 2022

            17.10.2.1. By Therapeutic Application

            17.10.2.2. By Drug Class

            17.10.2.3. By Formulation Type

            17.10.2.4. By Distribution Channel

    17.11. Russia

        17.11.1. Pricing Analysis

        17.11.2. Market Share Analysis, 2022

            17.11.2.1. By Therapeutic Application

            17.11.2.2. By Drug Class

            17.11.2.3. By Formulation Type

            17.11.2.4. By Distribution Channel

    17.12. Czech Republic

        17.12.1. Pricing Analysis

        17.12.2. Market Share Analysis, 2022

            17.12.2.1. By Therapeutic Application

            17.12.2.2. By Drug Class

            17.12.2.3. By Formulation Type

            17.12.2.4. By Distribution Channel

    17.13. Romania

        17.13.1. Pricing Analysis

        17.13.2. Market Share Analysis, 2022

            17.13.2.1. By Therapeutic Application

            17.13.2.2. By Drug Class

            17.13.2.3. By Formulation Type

            17.13.2.4. By Distribution Channel

    17.14. India

        17.14.1. Pricing Analysis

        17.14.2. Market Share Analysis, 2022

            17.14.2.1. By Therapeutic Application

            17.14.2.2. By Drug Class

            17.14.2.3. By Formulation Type

            17.14.2.4. By Distribution Channel

    17.15. Bangladesh

        17.15.1. Pricing Analysis

        17.15.2. Market Share Analysis, 2022

            17.15.2.1. By Therapeutic Application

            17.15.2.2. By Drug Class

            17.15.2.3. By Formulation Type

            17.15.2.4. By Distribution Channel

    17.16. Australia

        17.16.1. Pricing Analysis

        17.16.2. Market Share Analysis, 2022

            17.16.2.1. By Therapeutic Application

            17.16.2.2. By Drug Class

            17.16.2.3. By Formulation Type

            17.16.2.4. By Distribution Channel

    17.17. New Zealand

        17.17.1. Pricing Analysis

        17.17.2. Market Share Analysis, 2022

            17.17.2.1. By Therapeutic Application

            17.17.2.2. By Drug Class

            17.17.2.3. By Formulation Type

            17.17.2.4. By Distribution Channel

    17.18. China

        17.18.1. Pricing Analysis

        17.18.2. Market Share Analysis, 2022

            17.18.2.1. By Therapeutic Application

            17.18.2.2. By Drug Class

            17.18.2.3. By Formulation Type

            17.18.2.4. By Distribution Channel

    17.19. Japan

        17.19.1. Pricing Analysis

        17.19.2. Market Share Analysis, 2022

            17.19.2.1. By Therapeutic Application

            17.19.2.2. By Drug Class

            17.19.2.3. By Formulation Type

            17.19.2.4. By Distribution Channel

    17.20. South Korea

        17.20.1. Pricing Analysis

        17.20.2. Market Share Analysis, 2022

            17.20.2.1. By Therapeutic Application

            17.20.2.2. By Drug Class

            17.20.2.3. By Formulation Type

            17.20.2.4. By Distribution Channel

    17.21. GCC Countries

        17.21.1. Pricing Analysis

        17.21.2. Market Share Analysis, 2022

            17.21.2.1. By Therapeutic Application

            17.21.2.2. By Drug Class

            17.21.2.3. By Formulation Type

            17.21.2.4. By Distribution Channel

    17.22. South Africa

        17.22.1. Pricing Analysis

        17.22.2. Market Share Analysis, 2022

            17.22.2.1. By Therapeutic Application

            17.22.2.2. By Drug Class

            17.22.2.3. By Formulation Type

            17.22.2.4. By Distribution Channel

    17.23. Israel

        17.23.1. Pricing Analysis

        17.23.2. Market Share Analysis, 2022

            17.23.2.1. By Therapeutic Application

            17.23.2.2. By Drug Class

            17.23.2.3. By Formulation Type

            17.23.2.4. By Distribution Channel

18. Market Structure Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Market Share Analysis of Top Players

        18.3.1. By Regional

        18.3.2. By Therapeutic Application

        18.3.3. By Drug Class

        18.3.4. By Formulation Type

        18.3.5. By Distribution Channel

19. Competition Analysis

    19.1. Competition Deep Dive

        19.1.1. Teva

            19.1.1.1. Overview

            19.1.1.2. Product Portfolio

            19.1.1.3. Profitability by Market Segments

            19.1.1.4. Sales Footprint

            19.1.1.5. Strategy Overview

                19.1.1.5.1. Marketing Strategy

                19.1.1.5.2. Product Strategy

                19.1.1.5.3. Channel Strategy

        19.1.2. Abbott Laboratories

            19.1.2.1. Overview

            19.1.2.2. Product Portfolio

            19.1.2.3. Profitability by Market Segments

            19.1.2.4. Sales Footprint

            19.1.2.5. Strategy Overview

                19.1.2.5.1. Marketing Strategy

                19.1.2.5.2. Product Strategy

                19.1.2.5.3. Channel Strategy

        19.1.3. Novartis

            19.1.3.1. Overview

            19.1.3.2. Product Portfolio

            19.1.3.3. Profitability by Market Segments

            19.1.3.4. Sales Footprint

            19.1.3.5. Strategy Overview

                19.1.3.5.1. Marketing Strategy

                19.1.3.5.2. Product Strategy

                19.1.3.5.3. Channel Strategy

        19.1.4. Mylan

            19.1.4.1. Overview

            19.1.4.2. Product Portfolio

            19.1.4.3. Profitability by Market Segments

            19.1.4.4. Sales Footprint

            19.1.4.5. Strategy Overview

                19.1.4.5.1. Marketing Strategy

                19.1.4.5.2. Product Strategy

                19.1.4.5.3. Channel Strategy

        19.1.5. Pfizer

            19.1.5.1. Overview

            19.1.5.2. Product Portfolio

            19.1.5.3. Profitability by Market Segments

            19.1.5.4. Sales Footprint

            19.1.5.5. Strategy Overview

                19.1.5.5.1. Marketing Strategy

                19.1.5.5.2. Product Strategy

                19.1.5.5.3. Channel Strategy

20. Assumptions & Acronyms Used

21. Research Methodology

Recommendations

Healthcare

Super Generics Market

July 2023

REP-GB-4126

346 pages

Healthcare

Generic Oncology Drugs Market

October 2022

REP-GB-8961

200 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Branded Generics Market

Schedule a Call